Entries by Citron Research

, ,

Citron Exposes More Lies and Deception From Cyberdyne

Cyberdyne stock was up over 10% this week as the company put out a press release that told investors that the company’s regenerative treatment technology had been featured in Nature Magazine as a medical breakthrough.

再生治療技術が、ネイチャーマガジンで、医療の飛躍的進歩 として紹介されたというプレスリリースを公開し、サイバー ダインの株は、今週10%以上上昇している。

, ,

Mallinckrodt CEO FRAUD exposed by the new Medicare Drug Dashboard

Mallinckrodt Stock Target Price – $20   Dear Readers, It has taken too much time but now the truth is out about Mallinckrodt ($MNK). The newly published Medicare dashboard proves that: 1.  As insurance companies have clamped down on reimbursement, tax-inverted Mallinckrodt has dug deeper into the pockets of taxpayer-funded Medicare to peddle its medically […]


Citron Calls for Investigation of Cyberdyne CEO For Materially Misleading Claims — Citron Reiterates 300¥ Target Price

  Citron Research Calls on Japan’s Securities and Exchange Surveillance Commission to Immediately Initiate Investigation of Cyberdyne CEO For Materially Misleading Claims Cyberdyne Is Intentionally Misleading Investors Citron Reiterates 300¥ Target Price for Shares Japan’s SESC should immediately investigate statements that are being made on the Cyberdyne (TYO:7779) website by its CEO for the purpose of […]


Alliance Data Systems: If You Don’t Like the Answer, Just Change the Question!

Citron Target on Alliance Data Systems Corp is 50% Near-Term Downside   This month Citron Research celebrates its 15th year of publication — exposing, for lack of a better term, “market inefficiencies”. This neutral-sounding moniker is occasionally an accident … but rarely.  Most often it exploits the shallowness of Wall Street’s “insight” with management’s intentional […]